{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-031563","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.167429+00:00","generated_at":"2026-06-01T01:00:37.568736+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elicio reports ELI-002 7P Phase 1a DFS not yet reached at 4.9mg; biomarker responders have no progression","bullets":["Median DFS not reached in 14 patients; median follow-up 29.1 weeks.","At 4.9mg AMP-peptide (n=8), median DFS not reached vs 12.6 weeks for 1.4mg (n=6).","Patients with tumor biomarker reduction had zero progression events; non-responders had median DFS 11.0 weeks.","Above-median T cell responders had no progression events as of May 24, 2024 data cutoff.","Phase 2 interim analysis (135 patients) expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-031563","json":"https://secwatch.observer/filing/0001140361-24-031563.json","markdown":"https://secwatch.observer/filing/0001140361-24-031563.md","text":"https://secwatch.observer/filing/0001140361-24-031563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/0001140361-24-031563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/ny20031755x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:00:37.568736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}